Pfizer Quality Improvement Request for Proposals: Implementing Shared Decision Making in Hemophilia Patient Care
Pfizer funds projects that use shared decision making, patient-reported outcomes, and care algorithms to improve hemophilia care and patient engagement in the U.S.
Funder: Pfizer Inc.
Due Dates: July 21, 2026: Submission Deadline (full application) — applications due by 23:59 Eastern Standard Time (New York, GMT -5)
Funding Amounts: Up to $30,000 per project (direct + indirect costs, max 28% overhead); estimated total budget is $60,000; project length up to 18 months
Summary: Supports quality improvement projects integrating shared decision making, patient-reported outcomes, and care algorithms to enhance hemophilia patient care and engagement.
Key Information: Only organizations (not individuals or unaffiliated medical practice groups) in the U.S. are eligible; IRB approval required before project start if applicable.
Description
This grant opportunity from Pfizer Inc. is designed to support quality improvement (QI) projects that implement shared decision making (SDM) tools, patient-reported outcomes (PROs), and care algorithms in hemophilia patient care within the United States. The goal is to foster effective communication and collaboration among patients, caregivers, and multidisciplinary healthcare teams, while addressing barriers such as geographic, gender, and racial disparities. Projects are encouraged to propose system-based changes, empower patients in treatment decisions, and utilize innovative methods (including digital tools and remote monitoring) for collecting and applying PROs. The emphasis is on sustainable, measurable improvements that enhance patient engagement and align care with individual values and preferences.
